> Research Use Only (RUO) Disclaimer: This guide describes liraglutide dosing and protocols as documented in peer-reviewed clinical literature and FDA-approved prescribing information. It is provided for educational and research purposes only. Liraglutide (Victoza®, Saxenda®) is an FDA-regulated prescription medication. Any use outside of a licensed medical or institutional research setting may be illegal. Consult a qualified healthcare professional before using any pharmaceutical compound.
---
What Is Liraglutide?
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with 97% structural homology to endogenous human GLP-1. Its 26-amino acid sequence differs from native GLP-1 in two critical ways: a lysine-to-arginine substitution at position 34, and the attachment of a C-16 fatty acid chain via a glutamate spacer at position 26. These modifications enable reversible albumin binding, dramatically reducing renal clearance and extending the plasma half-life to approximately 13 hours — sufficient to support once-daily subcutaneous administration.
First approved by the FDA in 2010 as Victoza® (1.2–1.8 mg) for glycemic control in type 2 diabetes, liraglutide received a second approval in 2014 as Saxenda® (3.0 mg) for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. It was the first GLP-1 receptor agonist approved specifically for weight management — predating semaglutide's obesity indication by nearly six years.
→ See our Liraglutide Research Profile for a complete mechanistic breakdown and pharmacokinetics.
---
Research Forms vs. Approved Formulations
Understanding the difference between commercial and research-grade liraglutide is essential context for any protocol discussion.
FDA-Approved Formulations
| Product | Indication | Dose Range | Delivery |
|---|---|---|---|
| Victoza® (Novo Nordisk) | Type 2 diabetes | 1.2 mg or 1.8 mg once daily | Pre-filled pen |
| Saxenda® (Novo Nordisk) | Obesity / weight management | 3.0 mg once daily (titrated) | Pre-filled pen |
Both formulations ship as ready-to-inject solutions in multi-dose pens. No reconstitution is required — the pen dial selects the dose in milligrams directly.
Research-Grade / Lyophilized Forms
Generic liraglutide entered the market in 2024 following patent expiration. Research-grade liraglutide is typically sold as a lyophilized (freeze-dried) powder in vials ranging from 2 mg to 10 mg. This format requires reconstitution before use and is intended for laboratory and institutional research — not human administration outside clinical trial settings.
> Research-grade liraglutide is not FDA-approved and has not undergone the same purity, sterility, and dosing validation as commercial formulations. Third-party certificate of analysis (CoA) with ≥99% purity by HPLC should be the minimum sourcing criterion.
---
Reconstitution Protocol for Research-Grade Powder
Research protocols using lyophilized liraglutide require reconstitution with bacteriostatic water (BAC water) — sterile water containing 0.9% benzyl alcohol, which inhibits microbial contamination and extends vial stability after opening.
Standard Reconstitution Math
The target is a concentration that makes dose measurement practical on an insulin syringe (100 units = 1 mL, so 1 unit = 0.01 mL):
| Vial Size | BAC Water Volume | Resulting Concentration | Notes |
|---|---|---|---|
| 5 mg (5,000 mcg) | 2 mL | 2.5 mg/mL (2,500 mcg/mL) | Practical for low-titration steps |
| 10 mg (10,000 mcg) | 4 mL | 2.5 mg/mL | Consistent concentration, larger volume |
| 10 mg (10,000 mcg) | 2 mL | 5.0 mg/mL | High concentration; smaller draw volumes |
Example draw volumes at 2.5 mg/mL:
- •0.6 mg dose → 0.24 mL → 24 units on a 100-unit insulin syringe
- •1.2 mg dose → 0.48 mL → 48 units
- •1.8 mg dose → 0.72 mL → 72 units
- •2.4 mg dose → 0.96 mL → 96 units
- •3.0 mg dose → 1.20 mL → requires two draws or 5 mg/mL concentration
Reconstitution Steps
1. Allow both the vial and BAC water to equilibrate to room temperature (~15 minutes)
2. Wipe both vial stoppers with an alcohol swab; allow to dry
3. Draw the target BAC water volume into a syringe
4. Insert the needle at an angle to direct water against the inside wall of the vial, not directly onto the powder
5. Gently swirl — do not shake vigorously (shaking causes aggregation)
6. Allow to dissolve for 2–3 minutes; the solution should be clear and colorless
7. Label the vial with date, concentration, and initials; refrigerate immediately
> Never use plain sterile water — without benzyl alcohol, reconstituted peptide solutions degrade rapidly and support microbial growth. BAC water extends vial usability to approximately 28 days when refrigerated.
---
Subcutaneous Injection Protocol
Injection Sites
Liraglutide is administered subcutaneously into one of three primary sites:
| Site | Notes |
|---|---|
| Abdomen | 2 inches from navel; most consistent absorption |
| Anterior thigh | Outer upper thigh; slightly slower absorption |
| Upper arm (posterior) | Requires assistance or auto-injector for self-administration |
Rotate sites systematically — for example, abdomen on weekdays, thigh on weekends — to minimize local tissue reactions. Avoid injecting within 1 inch of a previous injection site or into areas with active bruising, scar tissue, or lipodystrophy.
Injection Technique
1. Cleanse site with alcohol swab; allow to dry completely
2. Pinch a fold of skin between thumb and forefinger (1–2 inch fold)
3. Insert needle at 45° or 90° depending on subcutaneous tissue depth
4. Inject slowly; release skin fold; remove needle
5. Apply light pressure; do not rub (rubbing accelerates absorption unpredictably)
Timing: Liraglutide can be injected at any time of day, independent of meals. Consistency — same time each day — is generally recommended in trial protocols to standardize exposure windows.
---
Dose Escalation Schedule from LEADER/SCALE Trial Data
The primary escalation schedule used across the SCALE obesity program and the LEADER cardiovascular outcomes trial was designed to minimize gastrointestinal adverse events, particularly nausea, which peaks early in treatment and improves substantially after 4–8 weeks.
Standard Titration Schedule (Saxenda® 3.0 mg Target)
| Week | Daily Dose | Rationale |
|---|---|---|
| Week 1 | 0.6 mg | Initiation / GI adaptation |
| Week 2 | 1.2 mg | First titration step |
| Week 3 | 1.8 mg | Intermediate step |
| Week 4 | 2.4 mg | Near-maintenance step |
| Week 5+ | 3.0 mg | Maintenance (target) dose |
Tolerability adjustment: If a dose escalation step is poorly tolerated, the protocol allows a one-week hold at the current dose before the next step. Only one delay per step is allowed under standard SCALE protocols, meaning full escalation to 3.0 mg should complete within 6 weeks maximum.
Missed doses: If ≤3 days have elapsed since the last dose, resume at the current dose on the next scheduled day. If >3 consecutive days have been missed, reinitiate at 0.6 mg and repeat the full escalation — this reduces GI side effects that return after a significant gap.
T2D Dosing (Victoza® Protocol, LEADER Trial)
For glycemic control in type 2 diabetes, the approved starting dose is 0.6 mg for 1 week, followed by escalation to 1.2 mg. If additional glycemic control is needed, a further increase to 1.8 mg is permitted. The 0.6 mg dose is a tolerability step, not a therapeutic dose.
> The LEADER trial (9,340 participants, 32 countries) demonstrated that liraglutide significantly reduced major adverse cardiovascular events (MACE) versus placebo in T2D patients with established cardiovascular disease — a landmark finding that contributed to its expanded prescribing use.
---
Liraglutide vs. Semaglutide: A Dosing Snapshot
| Parameter | Liraglutide | Semaglutide |
|---|---|---|
| Half-life | ~13 hours | ~168 hours (7 days) |
| Injection frequency | Once daily | Once weekly |
| Max approved dose (obesity) | 3.0 mg/day | 2.4 mg/week |
| Titration duration | 4–5 weeks | 16–20 weeks |
| Weight loss (SCALE/STEP trials) | ~5–8% body weight | ~15% body weight |
| CV outcome trial | LEADER (cardiovascular benefit) | SUSTAIN-6 / SELECT |
| Years of post-marketing data | 15+ years | ~6 years |
The key tradeoff: semaglutide achieves roughly twice the weight reduction of liraglutide, but liraglutide's daily injection schedule provides more granular dosing control during titration and benefits from a much longer safety record.
→ See our full Liraglutide vs. Semaglutide Comparison for mechanistic and clinical data side-by-side.
---
Storage and Stability
Unopened Vials / Pens
- •Store at 2°C–8°C (36°F–46°F) — standard refrigerator temperature
- •Do not freeze — ice crystal formation disrupts peptide structure irreversibly
- •Keep away from direct light
- •Shelf life: Until printed expiration date under continuous refrigeration
After Reconstitution (Research-Grade Vials)
- •Refrigerate immediately after reconstitution
- •Use within 28 days (BAC water's benzyl alcohol limits, but earlier use preferred)
- •Do not freeze reconstituted solutions
- •Discard if solution is cloudy, discolored, or contains visible particles
Room Temperature Exposure
- •Once a pen or vial has been at room temperature (up to 30°C/86°F), a 30-day clock begins
- •This window cannot be extended by returning the product to refrigeration
- •Research vials left above 30°C should be discarded — heat accelerates peptide aggregation
> Peptide stability declines significantly above 30°C. Unlike small-molecule drugs, liraglutide's structural integrity cannot be assessed visually once thermal damage occurs.
---
Sourcing Quality Markers
Research institutions and qualified labs sourcing liraglutide should prioritize suppliers who provide:
1. Third-party Certificate of Analysis (CoA) — HPLC purity ≥99%, mass spectrometry molecular weight confirmation
2. Sterility testing — particularly important for injectable research applications
3. Cold-chain shipping — insulated packaging with gel packs; overnight or 2-day shipping preferred
4. Documented lot traceability — lot numbers tied to CoA; enables cross-referencing
5. Endotoxin testing — LAL (limulus amebocyte lysate) test results for research-grade injectables
> Generic versions of liraglutide (authorized generic Victoza® and Saxenda®) became available in the U.S. starting mid-2024 (Teva) and December 2024 (Hikma), which has expanded supply options for clinical research programs.
---
Price Comparison
Research-grade liraglutide pricing varies significantly by supplier, vial size, and purity specification. Key cost drivers:
- •Vial size: 5 mg vs. 10 mg — bulk usually lowers per-mg cost
- •Purity tier: Standard 98% vs. certified 99%+ with full CoA
- •Shipping tier: Cold-chain overnight vs. standard shipping affects viability
→ Use our Peptide Price Comparison Tool to compare liraglutide pricing across verified suppliers in real time.
---
Key Takeaways for Researchers
- •Liraglutide's once-daily injection schedule and 13-hour half-life make it one of the most operationally straightforward GLP-1 protocols in research settings
- •Standard titration runs 4–5 weeks from 0.6 mg to the 3.0 mg maintenance dose
- •Reconstitute with BAC water only; target 2.5 mg/mL for practical syringe math at low titration doses
- •Never freeze; discard reconstituted vials after 28 days
- •The LEADER and SCALE trials provide the most robust human dosing and safety data available for any GLP-1 receptor agonist, making liraglutide a strong benchmark compound for comparative research
---
> RUO Disclaimer: This article is for educational and research informational purposes only. Liraglutide (Victoza®, Saxenda®) is an FDA-approved prescription medication. Research-grade liraglutide is not FDA-approved. Information here is drawn from peer-reviewed literature and FDA prescribing information. Nothing in this article constitutes medical advice. Do not use any pharmaceutical compound without authorization from a licensed healthcare provider.
---
Related articles: Liraglutide Research Profile · Liraglutide vs. Semaglutide Comparison · Compare GLP-1 Peptide Prices